BIOMAT Database Logo BIOMAT Database Logo

Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy. 2007

P Peris, and L Alvarez, and S Vidal, and M A Martínez, and A Monegal, and N Guañabens
Services of Rheumatology, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain. 22848ppb@comb.es

OBJECTIVE To compare the effects of tiludronate and risedronate on Paget's disease activity assessed by biochemical markers of bone turnover and quantitative bone scintigraphy. METHODS An open-labeled non-randomized study was performed in 49 patients with Paget's disease who had completed treatment with tiludronate (400 mg/d) for 3 months (28 patients) or risedronate (30 mg/d) for 2 months (21 patients). Biochemical markers of bone turnover, including serum total alkaline phosphatase (TAP), bone alkaline phosphatase (BAP), procollagen type I N propeptide (PINP) and urinary N-terminal cross-linking telopeptide of type I collagen (NTX) were measured at baseline and at 6 and 12 months after the end of treatment. Quantitative bone scintigraphy at baseline and 6 months after the end of treatment was performed in all patients obtaining a scintigraphic activity index (SAI). RESULTS At baseline there were no significant differences in disease activity between both groups of patients, since markers of bone turnover as well as SAI were similar in both groups. The effects of tiludronate and risedronate in reducing the biochemical markers of bone turnover were comparable at 6 months (tiludronate vs risedronate: TAP -52% vs -43%; BAP -69% vs -56%; PINP -68% vs -63%; NTX -62% vs -59%) and at 12 months after the end of treatment (tiludronate vs risedronate: TAP -47% vs -36%; BAP -57% vs -46%; PINP -57% vs -52%; NTX -51% vs -52%). The effects of tiludronate and risedronate on SAI were also similar 6 months after the discontinuation of treatment. In addition, the percentage of patients who showed normalized serum TAP levels at 6 months after treatment were similar with both agents (74% with tiludronate and 70% with risedronate). CONCLUSIONS Tiludronate and risedronate given at the currently recommended dosages induce similar responses in Paget's disease activity.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010001 Osteitis Deformans A disease marked by repeated episodes of increased bone resorption followed by excessive attempts at repair, resulting in weakened, deformed bones of increased mass. The resultant architecture of the bone assumes a mosaic pattern in which the fibers take on a haphazard pattern instead of the normal parallel symmetry. Paget's Disease of Bone,Osseous Paget's Disease,Paget Disease of Bone,Paget Disease, Bone,Pagets Disease, Bone
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011347 Procollagen A biosynthetic precursor of collagen containing additional amino acid sequences at the amino-terminal and carboxyl-terminal ends of the polypeptide chains. Protocollagen,Procollagen Type M
D011877 Radionuclide Imaging The production of an image obtained by cameras that detect the radioactive emissions of an injected radionuclide as it has distributed differentially throughout tissues in the body. The image obtained from a moving detector is called a scan, while the image obtained from a stationary camera device is called a scintiphotograph. Gamma Camera Imaging,Radioisotope Scanning,Scanning, Radioisotope,Scintigraphy,Scintiphotography,Imaging, Gamma Camera,Imaging, Radionuclide
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D004164 Diphosphonates Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents. Bisphosphonate,Bisphosphonates
D005260 Female Females

Related Publications

P Peris, and L Alvarez, and S Vidal, and M A Martínez, and A Monegal, and N Guañabens
Tiludronate for Paget's disease of bone.
July 1997, The Medical letter on drugs and therapeutics,
P Peris, and L Alvarez, and S Vidal, and M A Martínez, and A Monegal, and N Guañabens
Paget's disease of bone: reduction of disease activity with oral risedronate.
January 1998, Bone,
P Peris, and L Alvarez, and S Vidal, and M A Martínez, and A Monegal, and N Guañabens
Tiludronate therapy for Paget's disease of bone.
November 1995, Bone,
P Peris, and L Alvarez, and S Vidal, and M A Martínez, and A Monegal, and N Guañabens
Tiludronate. A new treatment for an old ailment: Paget's disease of bone.
November 1999, Expert opinion on pharmacotherapy,
P Peris, and L Alvarez, and S Vidal, and M A Martínez, and A Monegal, and N Guañabens
Risedronate for Paget's disease of bone.
August 1998, The Medical letter on drugs and therapeutics,
P Peris, and L Alvarez, and S Vidal, and M A Martínez, and A Monegal, and N Guañabens
[Therapeutic effects of risedronate on Paget's disease of bone].
September 2006, Clinical calcium,
P Peris, and L Alvarez, and S Vidal, and M A Martínez, and A Monegal, and N Guañabens
Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
August 1996, Calcified tissue international,
P Peris, and L Alvarez, and S Vidal, and M A Martínez, and A Monegal, and N Guañabens
Paget's disease of bone treated with a five day course of oral tiludronate.
January 1993, Annals of the rheumatic diseases,
P Peris, and L Alvarez, and S Vidal, and M A Martínez, and A Monegal, and N Guañabens
A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group.
May 1999, The American journal of medicine,
P Peris, and L Alvarez, and S Vidal, and M A Martínez, and A Monegal, and N Guañabens
Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment.
March 2005, Bone,
Copied contents to your clipboard!